Boshoff said China would be a particularly important market for Lorbrena. While 4% of non-small cell lung cancer (NSCLC) patients globally have ALK-positive tumors, up to 7% of patients in China do. NSCLC is the most common type of lung cancer. ICE THERAPY SHOWN TO KILL BREAST CANCER ...
The article informs that the lung-cancer drug Xalkori from Pfizer Inc. has helped the patients who had previously been treated for the disease. The company mentioned that Xalkori worked better than two older cancer drugs in the late-stage clinical trial. It adds that the U.S. Food and Drug...
Cancer treatments are a priority for Pfizer. They brought in $12 billion in revenue for the drugmaker last year. But Pfizer has only marketed a couple first-generation ADC treatments, a spokeswoman said. Seagen has four treatments on the market. It also has a pipeline of drugs under develop...
intended to facilitate and expedite the development and review of new drugs to address an unmet medical need in the treatment of a serious or life-threatening condition.Similarly, EMA instituted PRIME (PRIority MEdicines) to support the development of medicines that target an unmet medical need. Th...
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. Yes - Neuroblastoma; Non-small cell lung cancer; Non-Hodgkin's lymphoma New Molecular EntityYes Highest Development Phases MarketedAnaplastic large cell lymphoma; Non-small cell lung cancer ...
EU approves endometrial, lung cancer drugs from GSK and J&J Both GSK and J&J have claimed pivotal approvals for growth-phase oncology therapies in the EU. Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ...
Scientists and drug makers are pioneering a new kind of clinical trial that changes the way cancer drugs are studied, potentially cutting both the time and cost of brining them to market. Instead of testing one drug at a time, a novel lung cancer study announced on Thursday will allow Britis...
Xalkori addresses just a sliver of the lung cancer population, but the drug’s $9,600-per-month price tag suggests it could still make a meaningful contribution to the company’s bottom line. Xalkori went from lab bench to market in less than seven years, thanks to the 2007 discovery ...
Pfizer’s gruelling trek to bring EGFR inhibitor dacomitinib to market has finally paid off, with the FDA approving it as a first-line therapy for non-small cell lung cancer (NSCLC). The second-generation EGFR tyrosine kinase inhibitor has been shown in trials to be more effective tha...
This accelerated approval is among the first in the industry to be conducted under the FDA’s Project FrontRunner, which seeks to support the development and approval of new cancer drugs for advanced or metastatic disease. “Historically, treatment options have been limited and out...